Severe upper gastrointestinal disorders in pembrolizumab‐treated non‐small cell lung cancer patient

Pembrolizumab is an immune checkpoint inhibitor that induces side effects called “immune‐related adverse events” (irAEs). Various types of organs are affected by irAEs, although reports of upper gastrointestinal disorders are rare. Here, we report a case of extensive inflammatory pathologies in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Onuki, Tsugitoshi, Morita, Eri, Sakamoto, Noritaka, Nagai, Yoshiaki, Sata, Masafumi, Hagiwara, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980602/
https://www.ncbi.nlm.nih.gov/pubmed/30065841
http://dx.doi.org/10.1002/rcr2.334
_version_ 1783327904555335680
author Onuki, Tsugitoshi
Morita, Eri
Sakamoto, Noritaka
Nagai, Yoshiaki
Sata, Masafumi
Hagiwara, Koichi
author_facet Onuki, Tsugitoshi
Morita, Eri
Sakamoto, Noritaka
Nagai, Yoshiaki
Sata, Masafumi
Hagiwara, Koichi
author_sort Onuki, Tsugitoshi
collection PubMed
description Pembrolizumab is an immune checkpoint inhibitor that induces side effects called “immune‐related adverse events” (irAEs). Various types of organs are affected by irAEs, although reports of upper gastrointestinal disorders are rare. Here, we report a case of extensive inflammatory pathologies in the oesophagus, stomach, duodenum, and jejunum after the administration of pembrolizumab for non‐small cell lung cancer.
format Online
Article
Text
id pubmed-5980602
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-59806022018-08-01 Severe upper gastrointestinal disorders in pembrolizumab‐treated non‐small cell lung cancer patient Onuki, Tsugitoshi Morita, Eri Sakamoto, Noritaka Nagai, Yoshiaki Sata, Masafumi Hagiwara, Koichi Respirol Case Rep Case Reports Pembrolizumab is an immune checkpoint inhibitor that induces side effects called “immune‐related adverse events” (irAEs). Various types of organs are affected by irAEs, although reports of upper gastrointestinal disorders are rare. Here, we report a case of extensive inflammatory pathologies in the oesophagus, stomach, duodenum, and jejunum after the administration of pembrolizumab for non‐small cell lung cancer. John Wiley & Sons, Ltd 2018-08-01 /pmc/articles/PMC5980602/ /pubmed/30065841 http://dx.doi.org/10.1002/rcr2.334 Text en © 2018 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Onuki, Tsugitoshi
Morita, Eri
Sakamoto, Noritaka
Nagai, Yoshiaki
Sata, Masafumi
Hagiwara, Koichi
Severe upper gastrointestinal disorders in pembrolizumab‐treated non‐small cell lung cancer patient
title Severe upper gastrointestinal disorders in pembrolizumab‐treated non‐small cell lung cancer patient
title_full Severe upper gastrointestinal disorders in pembrolizumab‐treated non‐small cell lung cancer patient
title_fullStr Severe upper gastrointestinal disorders in pembrolizumab‐treated non‐small cell lung cancer patient
title_full_unstemmed Severe upper gastrointestinal disorders in pembrolizumab‐treated non‐small cell lung cancer patient
title_short Severe upper gastrointestinal disorders in pembrolizumab‐treated non‐small cell lung cancer patient
title_sort severe upper gastrointestinal disorders in pembrolizumab‐treated non‐small cell lung cancer patient
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980602/
https://www.ncbi.nlm.nih.gov/pubmed/30065841
http://dx.doi.org/10.1002/rcr2.334
work_keys_str_mv AT onukitsugitoshi severeuppergastrointestinaldisordersinpembrolizumabtreatednonsmallcelllungcancerpatient
AT moritaeri severeuppergastrointestinaldisordersinpembrolizumabtreatednonsmallcelllungcancerpatient
AT sakamotonoritaka severeuppergastrointestinaldisordersinpembrolizumabtreatednonsmallcelllungcancerpatient
AT nagaiyoshiaki severeuppergastrointestinaldisordersinpembrolizumabtreatednonsmallcelllungcancerpatient
AT satamasafumi severeuppergastrointestinaldisordersinpembrolizumabtreatednonsmallcelllungcancerpatient
AT hagiwarakoichi severeuppergastrointestinaldisordersinpembrolizumabtreatednonsmallcelllungcancerpatient

Ejemplares similares